What is Iovance Biotherapeutics, Inc.'s R&D?

Iovance Biotherapeutics, Inc. (IOVA) reported R&D of $62.49M in Q1 2026.

How has Iovance Biotherapeutics, Inc.'s R&D changed year-over-year?

Iovance Biotherapeutics, Inc.'s R&D decreased by 17.7% year-over-year, from $75.97M to $62.49M.

What is the long-term trend for Iovance Biotherapeutics, Inc.'s R&D?

Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s R&D has grown at a 3.9% compound annual growth rate (CAGR), from $259.04M to $301.71M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Iovance Biotherapeutics, Inc. IOVA R&D

R&D at other companies

Bristol-Myers SquibbBMY

$2.65B+17.4%

ImmunomeIMNM

$46.38M+25.8%

Nuvation BioNUVB

$35.05M+42.5%

Immunovant, Inc.IMVT

$142.29M+51.9%

Viridian Therapeutics, Inc.VRDN

$77.63M+1.0%

ImmunityBio, Inc.IBRX

——

Segments

By segment

See full

Single Reportable$57.37M-13.1%

Other financials

Income statement

See full

Revenue$71.4M+44.8%

Gross profit$28.9M+338%

Operating income-$81.0M+33.1%

Net income-$79.0M+32.0%

EPS (diluted)-$0.19+47.2%

Balance sheet

See full

Cash & equivalents$196.5M+14.5%

Total debt$46.8M-11.3%

Total equity$721.8M-6.0%

Total assets$925.7M-4.2%

Cash flow

See full

Operating cash flow-$72.1M+30.5%

CapEx$6.6M+6.4%

Free cash flow-$78.7M+28.4%

Valuation

See full

Market cap$1.98B+32.4%

Enterprise value$1.83B+33.2%

P/S6.9×-0.1×

Profitability

See full

Gross margin36.7%+4.1pp

Operating margin-127.2%-31.0pp

Net margin-123.9%-28.4pp

FCF margin-106.8%-27.5pp

Returns & leverage

See full

Return on equity-47.5%-3.7pp

Debt / equity0.1×0.0×

Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s R&D?: Iovance Biotherapeutics, Inc. (IOVA) reported R&D of $62.49M in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s R&D changed year-over-year?: Iovance Biotherapeutics, Inc.'s R&D decreased by 17.7% year-over-year, from $75.97M to $62.49M.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s R&D?: Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s R&D has grown at a 3.9% compound annual growth rate (CAGR), from $259.04M to $301.71M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.